Idexx Laboratories, Inc (IDXX) Insider Activity: Key Updates for Investors

A recent SEC filing from Idexx Laboratories, Inc (NASDAQ: IDXX) revealed that Director M. Anne Szostak sold company shares valued at approximately $1.42 million on August 22, 2025. The transaction involved 2,187 shares sold at an average price of $647.33 per share. Following this sale, Szostak now owns 262 shares, estimated to be worth around $190,000.

Shortly afterward, Margaret Anne Szostak purchased 2,187 shares, for total proceeds of roughly $1.42 million.

Earlier, Executive Vice President Michael G. Erickson sold 406 shares of Idexx Laboratories stock, valued at about $263,813, at a price of $649.96 per share. Post-transaction, Erickson holds 11,287 shares, estimated to be worth approximately $8.15 million.

Analyst Ratings and Coverage Updates

Analyst activity surrounding Idexx Laboratories has remained active throughout the year:

• Stifel recently upgraded its rating on IDXX from “Hold” to “Buy.”
• UBS began covering the stock in October 2025 with a “Neutral” rating.
• BTIG Research reiterated its “Buy” recommendation on August 5, 2025.
• Jefferies initiated coverage on July 1, 2025, also assigning a “Buy” rating.
• Earlier, on December 2, 2024, Leerink Partners began coverage with an “Outperform” rating and a $500 price target

IDXX Stock Price Performance

As of November 5, 2025, shares of Idexx Laboratories, Inc closed down slightly by 0.11%, ending the day at $722.12. Despite the minor dip, the stock has gained 13.83% over the past five trading days.

Since the start of 2025, IDXX shares have surged 77.46%, and are up 74.66% compared to a year ago. The stock reached a 52-week high of $735.00 on November 3, 2025, and a 52-week low of $356.14 on April 9, 2025.

Support and Resistance Levels

Technical analysis shows key support and resistance areas for IDXX:

• Support levels: $710.31 (primary), with a deeper support level at $698.49.
• Resistance levels: $730.22 (initial), followed by a higher level at $738.31.

Short Interest Overview

Short interest in Idexx Laboratories declined notably as of October 15, 2025, falling by approximately 350,000 shares to 1.78 million shares in total. According to Yahoo Finance, the prior month’s short interest (September 15, 2025) stood at 2.12 million shares, marking a 19.42% decrease.

This drop in short positions may suggest improving investor confidence in the stock’s outlo